ERS Genomics

Executive Summary

ERS Genomics is a Dublin-based intellectual property licensing company that owns and manages a foundational CRISPR/Cas9 patent portfolio co-invented by Nobel Laureate Emmanuelle Charpentier. Founded in 2014, the company operates as a pure-play IP firm, offering non-exclusive licenses to academic and commercial entities worldwide. Its patents cover essential methods for CRISPR genome editing, making it a critical gatekeeper for the widespread adoption of this technology across therapeutic, agricultural, and industrial applications. Unlike biotech firms developing proprietary products, ERS Genomics generates revenue solely through licensing fees, which provides a scalable, low-risk business model but also ties its growth directly to the expansion of the CRISPR ecosystem and the strength of its IP enforcement. ERS Genomics has established a broad licensee base, including major pharmaceutical companies and research tool providers, but its financial performance is opaque due to its private status. The company's value is underpinned by the ongoing legal defense of its patent claims, particularly against challenges from entities like the Broad Institute. Looking forward, ERS Genomics is well-positioned to benefit from the rising number of CRISPR-based therapies entering clinical trials and the increasing demand for accessible IP licensing. However, the lack of product pipeline diversification and dependence on litigation outcomes introduces uncertainty. The company's conviction score reflects its strategic importance in the CRISPR landscape balanced against its single-source revenue and legal risks.

Upcoming Catalysts (preview)

• Q3 2026New Major Licensing Agreement with Top-Tier Pharma70% success
• TBDFavorable Patent Office Decision Strengthening CRISPR IP50% success
• Q4 2026Acquisition Interest from Larger IP Holding or Biotech Firm30% success